alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-10.16






Prepared by:



Jody L. Spencer, Esq.


Rogers & Hardin LLP


2700 International Tower


229 Peachtree Street, N.E.


Atlanta, Georgia 30303-1601



After recording, please return to:



Fidelity National Title Insurance Company


990 Hammond Drive, Suite 550


Atlanta, Georgia 30328


Attn: Ms. Cheryl Clark



LIMITED WARRANTY DEED




THIS INDENTURE, made and entered into as of the 10th day of January, 2012, by and between SAN
CARLOS ASSOCIATES, L.P., a Georgia limited partnership, whose address is 20 Mansell Court East,
Suite 200, Roswell, Georgia 30076 (hereinafter referred to as “Grantor”), and G&E HC REIT II
WESTMINSTER SNF, LLC, a Delaware limited liability company, whose address is c/o Grubb & Ellis
Healthcare REIT II, Inc., 1551 North Tustin Avenue, Suite 300, Santa Ana, California 92705, Attn:
Danny Prosky, President and COO (hereinafter referred to as “Grantee”) (the words “Grantor” and
“Grantee” to include their respective heirs, legal representatives, successors and assigns where
the context requires or permits);



W I T N E S S E T H, THAT:




GRANTOR, for and in consideration of the sum of TEN AND NO/100 DOLLARS ($10.00) and other good
and valuable consideration, in hand paid at and before the sealing and delivery of these presents,
the receipt whereof is hereby acknowledged, has granted, bargained, sold, aliened, conveyed and
confirmed, and by these presents does grant, bargain, sell, alien, convey and confirm unto said
Grantee, all that tract or parcel of land lying and being located in Fulton County, Georgia, and
being more particularly described in Exhibit “A” attached hereto and incorporated herein by
this reference (hereinafter referred to as the “Property”).



TO HAVE AND TO HOLD the Property, with all and singular the rights, members and appurtenances
thereof, to the same being, belonging, or in anywise appertaining, only to the proper use, benefit
and behoof of the said Grantee forever in FEE SIMPLE, subject to those matters listed on
Exhibit “B” attached hereto and incorporated herein by this reference.



AND THE SAID GRANTOR will warrant and forever defend the right and title to the Property unto
Grantee against the claims of all persons and entities whomsoever claiming by, through or under
Grantor.



IN WITNESS WHEREOF, Grantor has executed and sealed this Limited Warranty Deed on the day and
year first above written.



	 	 	 	 	 
	Signed, sealed and delivered in

the presence of:

	 	SAN CARLOS ASSOCIATES, L.P., a

Georgia limited partnership
	 	



	/s/ Philip M. Rees

	 	By: /s/ James J. Andrews
	 	[SEAL]
	 

	 	 
	 	 
	Unofficial Witness

	 	James J. Andrews, President
	 	

	/s/ Joan Hudson

	 	

	 	

	 

	 	

	 	

	Notary Public

	 	

	 	

	My commission expires:

	 	

	 	

	2/21/2014

	 	

	 	

	 

	 	

	 	







[NOTARIAL SEAL]



787482
EXHIBIT 24.2


                                                  UnionBanCal Corporation
                                                  February 26, 2003

WHEREAS, officers of UnionBanCal Corporation (the "Corporation") have made
presentations to the Audit Committee and the Board of Directors regarding the
Corporation's financial results for the year ended December 31, 2002; and

WHEREAS, THE Audit Committee has had adequate opportunity to review and comment
on such results; and

WHEREAS, based on the Audit Committee's discussion with management and the
independent auditors and the Audit Committee's review of the representation of
management and the report of the independent auditors to the Audit Committee,
the Audit Committee recommended that the Board of Directors include the audited
consolidated financial statements in the Company's Annual Report on Form 10-K
for the year ended December 31, 2002, to be filed with the Securities and
Exchange Commission;

NOW, THEREFORE, BE IT RESOLVED that the President and Chief Executive Officer,
the Deputy Chairman, the Vice Chairmen and the Executive Vice President and
Chief Financial Officer and such other officers of the Corporation as they shall
designate in writing, be, and they hereby are, authorized and empowered on
behalf of the Corporation to execute the Form 10-K, in substantially the form
submitted to the Board, and file it with the Securities and Exchange Commission
pursuant to the Securities Exchange Act of 1934, as amended, and with such other
governmental agencies or instrumentalities as such officers deem necessary or
desirable, and to prepare, execute, deliver and file any amendment or amendments
to the Form 10-K, as they may deem necessary or appropriate; and

FURTHER RESOLVED that David I. Matson, David A. Anderson and John H. McGuckin,
Jr., be, and each of them with full power to act without the other hereby is,
authorized and empowered to prepare, execute, deliver and file the Form 10-K and
any amendment or amendments thereto on behalf of and as attorneys for the
Corporation and on behalf of and as attorneys for any of the following: the
chief executive officer, the chief financial officer, the principal accounting
officer, and any other officer of the Corporation.


        I certify that the foregoing resolution was adopted by the Board of

Directors of UnionBanCal Corporation at the Regular Meeting of said Board held

on February 26, 2003.

        I further certify that the foregoing resolution now stands on the

records of the books of The Corporation and has not been modified, repealed or

set aside in any manner whatsoever And is now in full force and effect.

         Dated:  February 26, 2003



                                      _______________________________
                                      John H. McGuckin, Jr.
                                      Secretary
EXHIBIT 31.2
  CERTIFICATIONS
    Form 10-Q
      Rules 13a-15(e) 15d-15(e)) Rules 13a-15(f) 15d-15(f))
                Joseph
    S. Tesoriero
   Vice President and Chief Financial Officer
   51
[Federal Register Volume 89, Number 14 (Monday, January 22, 2024)]
[Notices]
[Pages 3932-3933]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01045]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2024-1 Phase 
I/II: Multiplexed Patient

[[Page 3933]]

Administered Diagnostics for Hepatitis B, Hepatitis C, and HIV 
(Topic 127).
    Date: February 15-16, 2024.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Rockville, MD 
20892 (Video Assisted Meeting).
    Contact Person: Stephen A. Gallo, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, MSC 9834, 
Rockville, MD 20852, (240) 669-2858, <a href="/cdn-cgi/l/email-protection#97e4e3f2e1f2b9f0f6fbfbf8d7f9feffb9f0f8e1"><span class="__cf_email__" data-cfemail="c0b3b4a5b6a5eea7a1acacaf80aea9a8eea7afb6">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: January 16, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-01045 Filed 1-19-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
HeinOnline -- 57 Fed. Reg. 13498 1992HeinOnline -- 57 Fed. Reg. 13499 1992HeinOnline -- 57 Fed. Reg. 13500 1992HeinOnline -- 57 Fed. Reg. 13501 1992HeinOnline -- 57 Fed. Reg. 13502 1992HeinOnline -- 57 Fed. Reg. 13503 1992HeinOnline -- 57 Fed. Reg. 13504 1992HeinOnline -- 57 Fed. Reg. 13505 1992HeinOnline -- 57 Fed. Reg. 13506 1992HeinOnline -- 57 Fed. Reg. 13507 1992HeinOnline -- 57 Fed. Reg. 13508 1992HeinOnline -- 57 Fed. Reg. 13509 1992HeinOnline -- 57 Fed. Reg. 13510 1992HeinOnline -- 57 Fed. Reg. 13511 1992HeinOnline -- 57 Fed. Reg. 13512 1992HeinOnline -- 57 Fed. Reg. 13513 1992HeinOnline -- 57 Fed. Reg. 13514 1992HeinOnline -- 57 Fed. Reg. 13515 1992HeinOnline -- 57 Fed. Reg. 13516 1992HeinOnline -- 57 Fed. Reg. 13517 1992HeinOnline -- 57 Fed. Reg. 13518 1992HeinOnline -- 57 Fed. Reg. 13519 1992HeinOnline -- 57 Fed. Reg. 13520 1992HeinOnline -- 57 Fed. Reg. 13521 1992HeinOnline -- 57 Fed. Reg. 13522 1992HeinOnline -- 57 Fed. Reg. 13523 1992HeinOnline -- 57 Fed. Reg. 13524 1992HeinOnline -- 57 Fed. Reg. 13525 1992HeinOnline -- 57 Fed. Reg. 13526 1992HeinOnline -- 57 Fed. Reg. 13527 1992
11TH COURT OF APPEALS

EASTLAND, TEXAS

JUDGMENT

In re Thomas E. Stafford, * Original Mandamus Proceeding

No. 11-18-00180-CR * July 19, 2018

* Per Curiam Memorandum Opinion

(Panel consists of: Willson, J., 

Bailey, J., and Wright, S.C.J., 

sitting by assignment)

 This court has considered Relator’s petition for writ of mandamus and 

concludes that the writ of mandamus should be dismissed for want of 

jurisdiction. Therefore, in accordance with this court’s opinion, the petition 

for writ of mandamus is dismissed.
**EXHIBIT 32.2**

 

Thefollowing certification accompanies the issuer’s quarterly report on Form10-QSB and is not filed, as provided in Release 33-8212.  34-47551 dated May 13, 2003.

 

**CERTIFICATION OF PRINCIPALFINANCIAL OFFICERPURSUANT TO 18 U.S.C. SECTION 1350**

 

Inconnection with the accompanying quarterly report on Form 10-QSB of CoastBancorp for the quarter ended June 30, 2003, I, Thomas J. Sherman, ChiefFinancial Officer of Coast Bancorp, hereby certify pursuant to 18 U.S.C.Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, that:

 

(1)                                  such quarterly report on Form 10-QSB of CoastBancorp for the quarter ended June 30, 2003, fully complies with therequirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934;and

 

(2)                                  the information contained in such quarterlyreport on Form 10-QSB of Coast Bancorp for the quarter ended June 30,2003, fairly presents, in all material respects, the financial condition andresults of operations of Coast Bancorp.

 

Asigned original of this written statement required by Section 906 has beenprovided to Coast Bancorp and will be retained by Coast Bancorp and furnishedto the Securities and Exchange Commission or its staff upon request.

 

 

Dated:  August 11, 2004

 

 
|   | /s/  Berta F. Olson                                     |   |
|--------|---------------------------------------------------------|--------|
|   | Berta  F. Olson                                         |
|   | Chief  Financial Officer  (Principal Financial Officer) |
|        |                                                         |        |  |

 

----
115TH CONGRESS 

2D SESSION H. R. 4925 

AN ACT 

To require the Administrator of the Federal Railroad Administration to implement certain recommendations for management and collection of railroad safety data. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 4925 EH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘FRA Safety Data Im3 provement Act’’. 

4 SEC. 2. RECOMMENDATIONS FOR MANAGEMENT AND COL5 LECTION OF RAILROAD SAFETY DATA. 

6 (a) IN GENERAL.—The Administrator of the Federal 

7 Railroad Administration shall develop a plan, and a 

8 timeline to carry out such plan, to implement the rec9 ommendations from the Inspector General Report No. 

10 ST2017045 of the Department of Transportation, issued 

11 on May 3, 2017, to the greatest extent possible, to improve 

12 the Federal Railroad Administration’s management and 

13 collection of railroad safety data. 

14 (b) IMPLEMENTATION.— 

15 (1) IN GENERAL.—Not later than 180 days 

16 after date of enactment of this Act, the Adminis17 trator shall submit the plan and timeline developed 

18 under subsection (a) to the Committee on Transpor19 tation and Infrastructure of the House of Represent20 atives and the Committee on Commerce, Science, 

21 and Transportation of the Senate. 

22 (2) REPORT.—The Administrator shall report 

23 annually to the committees on the implementation of 

24 such plan until implementation is complete. 
3 

•HR 4925 EH

1 SEC. 3. NO ADDITIONAL FUNDS AUTHORIZED. 

2 No additional funds are authorized to carry out the 

3 requirements of this Act. Such requirements shall be car4 ried out using amounts otherwise authorized. 

Passed the House of Representatives April 10, 2018. 

Attest: 

Clerk. 
115TH CONGRESS 

2D SESSION H. R. 4925 

AN ACT 

To require the Administrator of the Federal Railrailroad safety data. ommendations for management and collection of road Administration to implement certain rec-
<PAGE>


                                                                    Exhibit 99.1

                WRITTEN STATEMENT OF THE CHIEF EXECUTIVE OFFICER
                           PURSUANT TO 18 U.S.C. 1350


         Solely for the purposes of complying with 18 U.S.C. 1350, I, the
undersigned Chief Executive Officer of Liquidmetal Technologies (the "Company"),
hereby certifies, based on my knowledge, that the Quarterly Report on Form 10-Q
of the Company for the quarter ended March 31, 2003, (the "Report") fully
complies with the requirements of Section 13 (a) of the Securities Exchange Act
of 1934 and that information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.


/s/   John Kang
-----------------------------------------
John Kang, Chief Executive Officer
May 14, 2002
EXHIBIT 31.2

CERTIFICATIONS

I,
Bernard F. Denoyer, certify that:

1)    I
have reviewed this quarterly report on Form 10-Q of Callisto Pharmaceuticals, Inc.

2)    Based
on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3)    Based
on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4)    The
registrant's other certifying officer and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-14 and 15d-14) for the registrant and we have:



5)    The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions);



Date: May 17, 2010

/s/ BERNARD F. DENOYER Bernard F. Denoyer Senior Vice President, Finance


---



QuickLinks
<PAGE>
 
                                                                    EXHIBIT 23.1

                       CONSENT OF INDEPENDENT ACCOUNTANTS


                                        


     We consent to the incorporation by reference in these registration
statements of DM Management Company and subsidiary on Form S-8 (File Nos. 33-
71266, 33-71776, 33-72166, 33-86982, 333-03845 and 333-42183) of our reports
dated January 30, 1998, on our audits of the consolidated financial statements
and financial statement schedule of DM Management Company and subsidiary as of
December 27, 1997 and December 28, 1996 and for the fiscal year ended December
27, 1997, the six months ended December 28, 1996 and each of the two fiscal
years in the period ended June 29, 1996, which reports are included in this
Annual Report on Form 10-K.



                              COOPERS & LYBRAND L.L.P.



Boston, Massachusetts
March 27, 1998
Exhibit 32: Section 1350 Certifications

I, Barbara A. Manzolillo, Chief Financial Officer and Treasurer, certify this annual report on Form 10-K of Medical Information Technology, Inc. (MEDITECH) for the period ended December 31, 2008, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of MEDITECH.

January 30, 2009
(Date)

Barbara A. Manzolillo, Chief Financial Officer and Treasurer
(Signature)

I, A. Neil Pappalardo, Chief Executive Officer and Chairman, certify this annual report on Form 10-K of Medical Information Technology, Inc. (MEDITECH) for the period ended December 31, 2008, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of MEDITECH.

January 30, 2009
(Date)

A. Neil Pappalardo, Chief Executive Officer and Chairman
(Signature)
PMN – [ CBI ] Waste Template 

# [ CBI ]

# [ CBI ]
[Federal Register Volume 89, Number 15 (Tuesday, January 23, 2024)]
[Notices]
[Page 4291]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01142]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 2391-000]


PE Hydro Generation, LLC; Notice of Authorization for Continued 
Project Operation

    The license for the Warren Hydroelectric Project No. 2391 was 
issued for a period ending December 31, 2023.
    Section 15(a)(1) of the FPA, 16 U.S.C. 808(a)(1), requires the 
Commission, at the expiration of a license term, to issue from year-to-
year an annual license to the then licensee(s) under the terms and 
conditions of the prior license until a new license is issued, or the 
project is otherwise disposed of as provided in section 15 or any other 
applicable section of the FPA. If the project's prior license waived 
the applicability of section 15 of the FPA, then, based on section 9(b) 
of the Administrative Procedure Act, 5 U.S.C. 558(c), and as set forth 
at 18 CFR 16.21(a), if the licensee of such project has filed an 
application for a subsequent license, the licensee may continue to 
operate the project in accordance with the terms and conditions of the 
license after the minor or minor part license expires, until the 
Commission acts on its application. If the licensee of such a project 
has not filed an application for a subsequent license, then it may be 
required, pursuant to 18 CFR 16.21(b), to continue project operations 
until the Commission issues someone else a license for the project or 
otherwise orders disposition of the project.
    If the project is subject to section 15 of the FPA, notice is 
hereby given that an annual license for Project No. 2391 is issued to 
PE Hydro Generation, LLC for a period effective January 1, 2024, 
through December 31, 2024, or until the issuance of a new license for 
the project or other disposition under the FPA, whichever comes first. 
If issuance of a new license (or other disposition) does not take place 
on or before December 31, 2024, notice is hereby given that, pursuant 
to 18 CFR 16.18(c), an annual license under section 15(a)(1) of the FPA 
is renewed automatically without further order or notice by the 
Commission, unless the Commission orders otherwise.
    If the project is not subject to section 15 of the FPA, notice is 
hereby given that PE Hydro Generation, LLC is authorized to continue 
operation of the Warren Hydroelectric Project under the terms and 
conditions of the prior license until the issuance of a subsequent 
license for the project or other disposition under the FPA, whichever 
comes first.

    Dated: January 16, 2024.
Debbie-Anne A. Reese,
Acting Secretary.
[FR Doc. 2024-01142 Filed 1-22-24; 8:45 am]
BILLING CODE 6717-01-P
Exhibit 10.26

 

[Isola Group Ltd Letterhead]

 

We are delighted to offer you a position on the Board of Directors of Isola Group Ltd, a Cayman company in formation (“Isola”).  As you know, Isola is in the process of filing a Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933 in connection with its initial public offering of ordinary shares.  By signing below, you confirm the following:

 

1.               You accept nomination to the Board of Directors of Isola, and will begin service immediately.

 

2.               You hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a director of Isola in the Registration Statement, and any amendments thereto.  You also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.

 

3.               As an independent director, you will be entitled to compensation (annualized) of $75,000 in cash, and $25,000 in restricted stock, and if you serve as chair of the audit or compensation committee, $15,000, and if you serve as chair of any other Board committee, an additional $5,000.  The first stock grant will become effective at the close of the market on the day that our IPO closes.  Each grant will vest ratably over three years on each anniversary of the date of grant, provided you remain on the Board during such time.  The other terms of the grant will be governed by an equity plan and related grant documents under development.

 

 

Please signify your acceptance by signing below.

 

Very truly yours,

 

 

	
Raymond   P. Sharpe
    	
 
    
	
CEO   of Isola Group Ltd, a Cayman company in formation
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
Accepted   and Consented to this        day of            2011.
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
[Print   Name]